Cipher Pharmaceuticals Inc. (CPHRF)
CPHRF Stock Price Chart
Explore Cipher Pharmaceuticals Inc. interactive price chart. Choose custom timeframes to analyze CPHRF price movements and trends.
CPHRF Company Profile
Discover essential business fundamentals and corporate details for Cipher Pharmaceuticals Inc. (CPHRF) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
2 Feb 2006
Employees
6.00
Website
https://www.cipherpharma.comCEO
Craig J. Mull
Description
Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. Its commercial products include Epuris (CIP-ISOTRETINOIN), a formulation of the active ingredient isotretinoin for use in the treatment of severe acne; Ozenoxacin to treat adult and paediatric patients with impetigo; Actikerall, which is indicated for the treatment of palpable or moderately thick hyperkeratotic actinic keratosis; Vaniqa, a prescription cream that reduces the growth of unwanted facial hair in women; BRINAVESS, a treatment for sinus rhythm in adults; and AGGRASTAT, an intravenous anti-platelet drug. The company's licensed products comprise CIP-Isotretinoin; Lipofen (CIP-Fenofibrate), a formulation of the active ingredient fenofibrate used for the treatment of hyperlipidemia, a cholesterol disorder; and Conzip/Durela (CIP- Tramadol), a formulation of the active ingredient tramadol for the management of moderate to moderately severe pain. Its pipeline products include Trevyent, a vasodilatory prostacyclin analogue to treat pulmonary arterial hypertension; CF-101 for severe plaque psoriasis and rheumatoid arthritis; MOB-015, a topical formulation of terbinafine for the treatment of onychomycosis; and DTR-001, a tattoo removal cream. Cipher Pharmaceuticals Inc. was founded in 2000 and is headquartered in Oakville, Canada.
CPHRF Financial Timeline
Browse a chronological timeline of Cipher Pharmaceuticals Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 Nov 2025
Revenue estimate is $18.60M.
Earnings released on 7 Aug 2025
EPS came in at $0.22 surpassing the estimated $0.16 by +40.96%, while revenue for the quarter reached $13.38M , missing expectations by -25.70%.
Earnings released on 8 May 2025
EPS came in at $0.10 falling short of the estimated $0.11 by -5.66%, while revenue for the quarter reached $12.02M , missing expectations by -33.26%.
Earnings released on 18 Mar 2025
EPS came in at $0.13 falling short of the estimated $0.19 by -31.58%, while revenue for the quarter reached $11.82M , missing expectations by -31.02%.
Earnings released on 7 Nov 2024
EPS came in at $0.01 falling short of the estimated $0.14 by -92.14%, while revenue for the quarter reached $10.37M , missing expectations by -40.23%.
Earnings released on 8 Aug 2024
EPS came in at $0.12 surpassing the estimated $0.12 by +4.46%, while revenue for the quarter reached $5.30M , missing expectations by -19.02%.
Earnings released on 9 May 2024
EPS came in at $0.20 surpassing the estimated $0.10 by +101.80%, while revenue for the quarter reached $5.84M , missing expectations by -10.83%.
Earnings released on 14 Mar 2024
EPS came in at $0.32 surpassing the estimated $0.10 by +235.89%, while revenue for the quarter reached $5.06M , missing expectations by -22.81%.
Earnings released on 9 Nov 2023
EPS came in at $0.28 surpassing the estimated $0.07 by +296.86%, while revenue for the quarter reached $6.07M , missing expectations by -7.36%.
Earnings released on 10 Aug 2023
EPS came in at $0.12 surpassing the estimated $0.10 by +19.40%, while revenue for the quarter reached $5.29M , missing expectations by -32.29%.
Earnings released on 11 May 2023
EPS came in at $0.10 surpassing the estimated $0.10 by +2.80%, while revenue for the quarter reached $4.89M , missing expectations by -37.44%.
Earnings released on 16 Mar 2023
EPS came in at $0.77 surpassing the estimated $0.09 by +755.56%, while revenue for the quarter reached $4.91M , missing expectations by -37.14%.
Earnings released on 10 Nov 2022
EPS came in at $0.10 surpassing the estimated $0.09 by +11.11%, while revenue for the quarter reached $4.79M , missing expectations by -16.60%.
Earnings released on 21 Jul 2022
EPS came in at $0.08 falling short of the estimated $0.10 by -16.99%, while revenue for the quarter reached $5.56M , missing expectations by -13.16%.
Earnings released on 12 May 2022
EPS came in at $0.08 falling short of the estimated $0.09 by -9.13%, while revenue for the quarter reached $5.42M , missing expectations by -4.98%.
Earnings released on 17 Mar 2022
EPS came in at $0.11 matching the estimated $0.11, while revenue for the quarter reached $5.85M , missing expectations by -2.15%.
Earnings released on 11 Nov 2021
EPS came in at $0.05 falling short of the estimated $0.09 by -44.44%, while revenue for the quarter reached $4.51M , missing expectations by -42.20%.
Earnings released on 12 Aug 2021
EPS came in at $0.10 surpassing the estimated $0.08 by +25.00%, while revenue for the quarter reached $6.13M .
Earnings released on 13 May 2021
EPS came in at $0.05 surpassing the estimated -$0.09 by +155.56%, while revenue for the quarter reached $5.45M , missing expectations by -30.24%.
Earnings released on 18 Mar 2021
EPS came in at -$3.19 falling short of the estimated $0.07 by -4.65K%, while revenue for the quarter reached $6.15M , missing expectations by -21.27%.
Earnings released on 12 Nov 2020
EPS came in at $0.06 , while revenue for the quarter reached $4.85M .
CPHRF Stock Performance
Access detailed CPHRF performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.